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Purpose: The impact of acute rejection (AR) after liver transplantation (LT) for hepatocel-
lular carcinoma (HCC) on patient outcome is uncertain. This aim of this study is to 
investigate whether AR is associated with HCC relapse and overall survival.
Patients and Methods: Patients undergoing LT for HCC between 2001 and 2015 were 
retrospectively analyzed with regard to histopathological proven AR within the median time 
until recurrence. Cox’s regression analysis was conducted revealing risk factors for HCC 
recurrence.
Results: HCC recurred in 47 of 252 analyzed patients with a median time to recurrence of 20 
months. Patients with AR (28.6%) had a significantly higher frequency of recurrence compared 
to patients without AR (13.0%, p=0.002). Multiple Cox regression analyses identified AR within 
20 months to be an independent risk factor for HCC recurrence both as dichotomized (HR=2.91, 
95%CI: 1.30–6.53; p=0.009) and as a continuous variable (HR=1.81, 95%CI: 1.28–2.54; 
p=0.001). HCC recurrence and AR were associated with higher grades of liver fibrosis 
one year after LT, when compared to patients without AR (p=0.019).
Conclusion: Our results demonstrate an association of AR with HCC recurrence after LT 
with implications for intervals of monitoring in tumor surveillance. Graft fibrosis and 
immune mechanisms are potentially related and causal interactions are worth further 
investigation.
Keywords: histology, protocol liver biopsy, graft fibrosis, immunological mechanisms, 
predictors of tumor relapse
Introduction
The World Health Organization (WHO) reported hepatocellular carcinoma (HCC) 
to be the sixth most commonly diagnosed cancer and the fourth leading cause of 
cancer deaths worldwide in 2018.1 Potentially curative treatment strategies for HCC 
include liver transplantation (LT), liver resection (LR) and ablation. Among these 
options, LT is considered as first-line option for patients fulfilling benchmark 
criteria, especially for patients, in unsuitable condition for LR.2 Excellent long- 
term outcomes are achieved in selected HCC patients by LT as well as by LR with 
five-year survival rates between 60% and 70%.3–7 However, recurrent disease 
remains an persisting problem after LT with rates ranging from 9% to 16%.8,9 
A first peak of intrahepatic recurrence—considered to be due to metastatic spread— 
is typically seen within the first 24 months after LR, whereas a second peak is 
postulated to be associated with de novo tumors in fibrotic grafts.10
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Several oncological predictors for HCC recurrence are 
well known, eg vascular invasion, degree of differentia-
tion, tumor size, number of nodules and satellites.8,11–15 
During the past years different studies suggested some 
non-oncological risk factors in association with HCC 
recurrence, such as age, prolonged cold ischemia time 
(CIT; >10 h) and warm ischemia time (WIT; >50 min) as 
well as blood transfusion.16–21 Of note, biomarkers seem 
to play a key role in liver inflammation and ultimately 
tumor recurrence, such as being able to predict outcomes 
after LT.22 Particularly the neutrophil lymphocyte ratio 
(NLR) measured in the peripheral blood was found to be 
of importance in predicting outcome in several malignan-
cies, including HCC. Several studies found that preopera-
tive elevated NLR is associated with high risk of 
recurrence and death in patients with HCC undergoing 
LT.8,23–25
The incidence of acute rejection (AR) varies from 10% 
to 64% and its implications on patient outcomes after LT 
remains controversial.26–30 Toso et al stated that a history 
of AR is associated with a better postrecurrence survival 
after LT possibly linked to anticancer immunity.30 In con-
trast, other authors reported significantly increased risk of 
graft failure, mortality, and graft failure-related death 
regardless of primary liver disease but in association 
with AR.29 There is increasing evidence for the impor-
tance of immune responses in HCC; however, potential 
implications of AR on tumor recurrence after LT remain 
uncertain. Consequently, the aim of this study was to 
investigate associations between episodes of AR and 
HCC recurrence after LT.
Patients and Methods
Study Population
We analyzed all patients undergoing LT for HCC at the 
Department of Surgery, Campus Virchow-Klinikum, 
Charité—Universitätsmedizin Berlin between 
February 2001 and September 2015. Exclusion criteria 
were living donor LT (n=16), need for re-LT (n=22) or 
death within the median time to recurrence (20 months, 
n=38) and lost to follow-up (n=2).
The study focused on biopsy-proven AR after LT as 
potential risk factor for HCC recurrence. For this purpose, 
all liver biopsies were analyzed including routinely per-
formed per protocol biopsies after LT as well as non- 
routinely performed biopsies for suspected AR. Episodes 
of AR occurring within the median time until HCC 
recurrence (20 months) were considered. HCC recurrence 
was defined as any tumor burden independent of the site, 
eg hepatic recurrence or distant metastases. Charité Local 
Ethics Committee approved data analysis (EA2/150/13). 
Medical records were reviewed based on the ethics vote of 
the IRB without an additional consent from the patients 
studied. First, all patients signed their informed consent to 
review their medical records at the time of liver transplan-
tation. However, the retrospective study design was also 
causally related to this as a period of more than 13 years 
was studied, during which patients died. The privacy of all 
patients studied was kept confidential by anonymizing the 
data and following the Declaration of Helsinki. The own-
ers of the data set are the authors of the study and they 
have collected the data through a retrospective evaluation. 
All organs were donated voluntarily with written informed 
consent and this was conducted in accordance with the 
Declaration of Istanbul.
Data Collection
Preoperative demographic characteristics and clinical vari-
ables included recipient and donor age at time of LT, 
recipient sex, body mass index (BMI) (in kg/m2), etiology 
of chronic liver disease, laboratory studies (alpha- 
fetoprotein (AFP) ≤200 µg/L vs >200 µg/L, NLR ≤4 
vs >4, waiting time for LT ≤120 days vs >120 days, 
model of end-stage liver disease (MELD) score, beyond 
MILAN criteria (yes vs no) and bridging therapies to LT 
including LR, radiofrequency ablation (RFA) or transcath-
eter arterial chemoembolization (TACE) (yes vs no). 
Analyzed perioperative risk factors were CIT (>10 h) 
and WIT (>50 min). Oncological factors evaluated in the 
study were tumor size (>5 cm), >3 tumor nodules, bilobar 
HCC, T >2, vascular invasion and poor differentiation (G 
>2) in the explanted recipient liver (according to TNM 
classification at time of LT).
For patients undergoing LT with hepatitis C virus (HCV) 
viremia at time of transplant, duration of viremia after trans-
plantation, type of HCV treatment (interferon, IFN; riba-
virin, RBV; direct acting antiviral drugs, DAA) received 
post-LT and incidence of HCV recurrence were documented.
Immunosuppression
Standard immunosuppression (IS) regimens in our patient 
cohort consisted of calcineurin inhibitor (CNI)-based IS 
(FK506 rather than cyclosporine A; CyA) and low-dose 
steroid usage, with adjustments on an individual basis. 
Steroids were routinely tapered and stopped within three 
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months after LT. Combination with antimetabolites as 
mycophenolate mofetil (MMF) were indicated on an indi-
vidual basis, eg due to reduced renal function.
Baseline IS was reported in case of continuous appli-
cation of at least three months in the first year after LT 
(median of values collected at 1, 3, 6, 9 and 12 months). In 
addition, usage of mammalian target of rapamycin inhibi-
tors (mTORi—sirolimus, everolimus) was reported before 
diagnosis of recurrent disease or until last available fol-
low-up (in the no recurrence group).
Post-LT Aftercare
The standardized performed aftercare included per proto-
col liver biopsies, laboratory AFP level measurement and 
sonographic examination of liver parenchyma in regard to 
steatosis, fibrosis and suspicious lesions after six months, 
1, 3, 5, 7, 10, and 13 years post-LT. In case of suspected 
HCC recurrence, CT and/or MRI was performed. 
Recurrent disease was confirmed by radiological imaging 
in combination with elevated AFP levels or histopatholo-
gical confirmation either by biopsy or partial resection.
Histopathology
Expert pathologists routinely analyzed liver biopsies. 
Paraffin-embedded liver biopsies were stained with H&E, 
Masson–Golder, iron and periodic-Schiff reagent. 
Histopathologic evaluation of liver tissue focused on 
signs of AR, as well as the presence and grading of 
fibrosis, median inflammation grades (hepatitis), steatosis, 
and cholangitis. Fibrosis was staged using a scale by 
Desmet et al (0: absent, 1: mild without septa, 2: moderate 
with few septa, 3: numerous septa without cirrhosis and 4: 
cirrhosis).31 Inflammation grades were assessed according 
to the classification by Desmet et al (0: none, 1: minimal, 
2: mild, 3: moderate and 4: severe).31
Diagnosis and Therapy of AR
All ARs were histopathologically proven. No humoral 
rejections were included in this study. Common indica-
tions for non-protocol liver biopsy were elevated liver 
enzymes, cholestasis or liver dysfunction. The grading of 
severity of AR was classified according to Banff criteria 
and stratified as mild (score <5), moderate (5–6), and 
severe (7–9).32,33 According to histologically proven AR 
and clinical findings, treatment was initiated. 
Intravenous application of steroids represented the stan-
dard treatment of AR (methylprednisolone of 500 mg over 
three days). Moreover, dosage of CyA or FK506 was 
increased or MMF was added on an individual basis.
Statistical Analysis
For univariate analysis, continuous variables were reported 
as median (range), and categorical data as counts and 
percentages. Comparison of categorical data was per-
formed, by using Pearson’s chi-squared test or 
Fisher's exact test. Mann–Whitney U-test or Student’s 
t test were used for continuous variables. OS and HCC 
recurrence rates were calculated by using Kaplan–Meier 
survival analysis with the log rank test for between-group 
comparison. Time until tumor recurrence was defined as 
the date of LT until tumor recurrence and censored at date 
of last available follow-up or death from nontumor-related 
causes. A sub-analysis was used to identify differences 
between patients with and without recurrent disease in 
regard to occurrence of AR. Therefore patients were 
divided into AR and no AR groups and again divided 
into HCC recurrence and no HCC recurrence. In addition, 
patients with HCC recurrence were separated into early 
(within 24 months) and late recurrence (>24 months) and 
compared within these groups. A subgroup analysis for 
HCV patients only was performed (see Supplemental 
Table 1).
To evaluate the association between potential risk fac-
tors for HCC recurrence, we conducted a multiple Cox 
proportional hazard regression with variables that were 
significant on the univariate analysis (p<0.05). Cox pro-
portional regression analysis was used to develop 
a multiple model adjusting for the combined effects of 
pretransplant AFP >200 µg/L (yes vs no), preoperative 
NLR >4 (yes vs no), beyond MILAN (yes vs no), bilobar 
HCC expression (yes vs no), T grade >2 (yes vs no), 
grading >2 (yes vs no), and AR after LT (yes vs no) 
(model 1) or frequency of AR within 20 months 
(model 2). HRs were presented with 95%CI.
The statistical significance was set at p-value <0.05. 
All statistical analysis was performed using IBM SPSS 
Statistics version 22.
Results
Of 330 patients undergoing LT for HCC, 252 patients ful-
filled the defined criteria and were subsequently analyzed 
(Figure 1). The main underlying etiology for chronic liver 
disease was alcoholic liver disease (n=107, 42.5%), followed 
by chronic HCV (n=83, 32.9%). During a mean follow-up 
time of 94.5±47.5 months, 47 patients (18.7%) developed 
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recurrent disease. Of those one, two, three, and five-year 
recurrence rates were 21.3% (n=10), 57.4% (n=27), 70.2% 
(n=33), and 83.0% (n=39), respectively, with a median time 
until recurrence of 20 months (range: 5–108). Eight patients 
(17.0%) developed HCC recurrence in the liver graft, 16 
patients (34.0%) had extrahepatic metastases and 23 patients 
(48.9%) had intra- and extrahepatic recurrence.
Histopathological proven AR occurred in 91 patients 
(36.1%) within the first 20 months after LT. The frequency 
of disease recurrence was significantly higher in patients with 
AR (28.6%) compared to patients without AR (13.0%, 
p=0.002). AR episodes within the first 20 months were more 
frequent in patients with HCC recurrence, when compared to 
patients without HCC recurrence (p=0.001, Figure 1). 
Furthermore, there was a tendency toward more frequent 
ARs within the first 30 days after LT in the HCC recurrence 
group (p=0.137, Figure 1). Of patients with AR, those with 
recurrent disease revealed significantly more episodes of AR 
(p=0.014) and were characterized by significantly higher 
grades of fibrosis one year after LT when compared to patients 
without recurrence (p=0.019). When comparing patients with 
and without AR, CIT >10 h were less frequent, whereas 
hepatitis was more frequent in patients with AR (Table 1).
With regard to immunosuppression, there was no differ-
ence between the percentage of FK506 and CyA baseline 
usage (FK506: AR, n=85, 93.4%; no AR, n=150, 93.2%; 
p=0.942; CyA: AR, n=5, 5.5%; no AR, n=10, 6.2%, 
p=0.817) or between FK506 trough levels in patients with 
and without rejection (AR: 7.0, 1.3–12.3; no AR: 7.1, 1.0–13.5; 
p=0.711). Furthermore, there were no correlations between 
FK506 level and number of rejections (Spearman, r=–0.39; 
p=0.546). Correspondingly, no difference between percentage 
of FK506 usage on the one hand and recurrence on the other 
hand was found (no HCC recurrence, n=190, 92.7%; HCC 
recurrence, n=45, 95.7%, p=0.450). Usage of mTORi before 
HCC recurrence was also comparable between all groups 
(sirolimus: AR, n=18, 19.8%; no AR, n=28, 17.4%, p=0.637; 
everolimus: AR, n=5, 5.5%; no AR, n=13, 8.1%, p=0.445). 
Patients with recurrent disease received in 61.5% steroid bolus 
for first AR and patients without HCC recurrence in 61.9% of 
the cases (p=0.397). Only MMF was administered slightly 
more frequently in the group with rejections as opposed to 
the group without rejections (AR, n=55, 60.4%; no AR, n=65, 
40.4%, p=0.002). Clinical and oncological features as well as 
histopathologic biopsy parameters are shown in Table 1 and 
therapy regimens for patients with AR are listed in Table 2.
When comparing patients with early and late recurrent 
disease no significant differences with regard to preopera-
tive and postoperative course as well as histopathologic 
features were found (Table 3). There was a tendency 
toward higher preoperative AFP levels in early HCC 
recurrence patients (p=0.067), whereas late recurrence 
Figure 1 Frequency of acute rejections (AR) within 30 days and 20 months after OLT compared between no HCC recurrence and HCC recurrence groups. 
Notes: a0.5% of patients had three episodes of acute rejections within 20 months. b0.5% of patients had four episodes of acute rejections within 20 months.
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Table 1 Patient Characteristics and Perioperative Outcomes Compared Between Patients with Acute Rejection (AR) and without AR 
(No AR) Within 20 Months














Gender (male:female) 22:4 51:14 0.506 20:1 108:32 0.055 0.892
Recipient age (in years) 60 (33–72) 56 (21–70) 0.171 59 (45–70) 58.5 (40–70) 0.876 0.277
Donor age (in years) 55 (12–84) 59 (8–91) 0.527 57 (22–78) 55 (19–84) 0.853 0.589
Alcohol 12 (46.2) 29 (44.6) 12 (57.1) 54 (38.6)
HCV 9 (34.6) 22 (33.8) 4 (19.0) 48 (34.3)
HBV 2 (7.7) 4 (6.2) 1 (4.8) 19 (13.6)
Other 3 (11.5) 10 (15.3) 4 (19.2) 19 (13.6)
AFP >200 µg/L 6 (26.1) 9 (14.3) 0.202 6 (28.6) 11 (8.3) 0.006a 0.168
Time to transplant >120 
days
11 (42.3) 35 (56.5) 0.226 8 (38.1) 69 (50.4) 0.295 0.595
Pretransplant MELD 11 (6–21) 11 (6–36) 0.654 14 (7–32) 11 (1–40) 0.174 0.112
Preoperative treatment 20 (76.9) 42 (64.6) 0.255 10 (47.6) 79 (56.8) 0.428 0.052
Mortality (%) 24 (92.3) 17 (26.2) <0.001a 20 (95.2) 45 (32.1) <0.001a 0.470
OS (months) 39 (20–165) 98 (34–212) <0.001a 48 (20–157) 104 (21–219) <0.001a 0.210
Time until recurrence 
(months)
20 (5–120) – 24 (8–99) – 0.840
NLR >4 6 (37.5) 12 (24.0) 0.291 10 (66.7) 26 (26.5) 0.002a 0.519
NLR >5 3 (18.8) 5 (10.0) 0.351 7 (46.7) 17 (17.3) 0.010a 0.125
CIT (min) 552 (120–1118) 518 (147–846) 0.215 569 (18–1119) 572 (77–1274) 0.333 0.186
CIT >10 h 10 (38.5) 15 (23.1) 0.137 10 (47.6) 54 (39.1) 0.460 0.042a
WIT (min) 42 (31–65) 45 (16–80) 0.663 47 (35–70) 46 (18–115) 0.528 0.056
WIT >50 min 4 (20.0) 10 (19.2) 0.941 5 (29.4) 35 (31.3) 0.879 0.076
T3/T4 stage 7 (26.9) 5 (7.8) 0.016a 11 (52.4) 14 (10.1) <0.001a 0.610
HCC bilobar 13 (50.0) 14 (21.5) 0.007a 9 (42.9) 33 (23.7) 0.063 0.560
Poor differentiation (G >2) 9 (36.0) 6 (11.1) 0.009a 8 (38.1) 18 (14.9) 0.011a 0.901
Vascular invasion 8 (34.8) 9 (16.4) 0.072 11 (55.0) 18 (14.9) <0.001a 0.831
Within MILAN 11 (42.3) 44 (67.7) 0.025a 4 (19.0) 94 (68.6) <0.001a 0.804
Number of AR within 
20 months
1 (1–3) 1 (1–4) 0.014a – – –
Extrahepatic recurrence 11 (42.3) 5 (23.8)
Intrahepatic recurrence 0 (0.0) 8 (38.1) 0.002a
Both extra- and 
intrahepatic recurrence
15 (57.5) 8 (38.1)
Biopsy after 1 year
Fibrosis 17 (89.5) 36 (80.0) 0.359 12 (92.3) 80 (77.7) 0.220 0.570
Stage, median 2 (0–3) 1 (0–3) 0.019a 1 (0–2) 1 (0–3) 0.518 0.105
Steatosis 13 (72.2) 40 (80.0) 0.495 8 (57.1) 74 (66.7) 0.480 0.074
-In % 20 (0–80) 12.5 (0–80) 0.931 25 (0–50) 10 (0–90) 0.601 0.505
Hepatitis 16 (88.9) 39 (78.0) 0.314 9 (64.3) 75 (67.0) 0.841 0.036a
Grade, median 1 (0–3) 1 (0–3) 0.158 1 (0–1) 1 (0–4) 0.425 0.010a
Notes: aSignificant results. *p-value comparing HCC recurrence with AR and HCC recurrence without AR. 
Abbreviations: AR, acute rejection; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; OS, overall survival; NLR, neutrophil 
lymphocyte ratio; CIT, cold ischemia time; WIT, warm ischemia time.
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tended toward prolonged cold ischemia times (p=0.078). 
Out of 47 patients with recurrent disease 33 (70.2%) were 
histologically proven, whereas 14 cases were radiologi-
cally confirmed in combination with elevated AFP levels 
with a median of 7063 µg/L.
Risk Factor Analysis for HCC Recurrence
In univariate analysis, AFP >200 µg/L, NLR >4, HCC 
beyond MILAN, tumor size >5 cm and >3 nodules, bilobar 
HCC, poor differentiation (G >2), T3 and T4 stage and 
vascular invasion were associated with tumor recurrence 
(Table 4). AR within the first 20 months after LT were 
associated with recurrent disease as a continuous variable 
(HR=1.78, 95%CI: 1.35–2.35, p<0.001) as well as 
a dichotomized variable (HR=2.39, 95%CI: 1.34–4.25, 
p=0.003). Therefore, two Cox regression models were 
established: model 1 with AR as a dichotomized variable 
(yes vs no) and model 2 with AR as a a continuous 
variable (number of AR events) (Table 4).
Statistically significant risk factors on univariate ana-
lysis were considered in multiple Cox analyses. Instead of 
taking tumor size, number, and vascularisation into 
account, the T stage was used.
AR within 20 months as a dichotomized variable 
(HR=2.91, 95%CI: 1.30–6.53, p=0.009) and as 
a continuous variable (HR=1.81, 95%CI: 1.28–2.54, 
p=0.001) were found to be statistically significant predic-
tors for HCC-recurrence after LT. Other factors associated 
with HCC recurrence were baseline NLR >4, T3 or T4 
stage of the tumor and bilobar HCC.
Discussion
Herein we report on the association between histopatho-
logical proven AR and HCC recurrence after LT for 
HCC. We showed that the occurrence of AR within the 
first 20 months after LT is an independent risk factor for 
HCC recurrence. While reported incidence rates of AR 
after LT vary, the 36.1% incidence we observed is gen-
erally in accordance with other studies.26–28,34 It has 
been described that younger recipient age, lack of renal 
impairment, higher aspartate aminotransferase (AST) 
levels, fewer human leukocyte antibody (HLA)-DR 
matches, longer cold ischemia times, and older donors 
were independently associated with an increased inci-
dence of AR.27 Other reports on AR after LT discuss 
biliary complications as a potential cause and summarize 
that most ARs respond to bolus corticosteroid therapy.28 
Our study revealed that overall mortality and survival 
regardless of the occurrence of AR was comparable in 
patients without recurrent disease.29
We hypothesize that the interplay of three key factors 
eventually determines the relationship between AR and 
tumor recurrence:
First, associations between immunosuppression and the 
risk of tumor recurrence after LT for HCC have been 
demonstrated previously.35 In our study cohort baseline 
FK506 usage during the first year post-LT was comparable 
between patients with and without HCC recurrence. This 
point is important because one could have imagined that 
associated number of rejections had more to do with the 
tailored immunosuppressive games in HCC patients at 
high oncological risk than with HCC recurrence itself. Of 
note, there were no correlations between FK506 level and 
number of rejections, respectively. MMF was indeed 
administered slightly more frequently in the group with 
rejections as opposed to the group without rejections, 
however, the clinical relevance is considered low in rela-
tion to the available literature.36,37 With regard to the 
use of mTORi before HCC recurrence, also no differences 
were found between both groups. This is important to 
Table 2 Therapy of First AR Compared Between HCC 










Mild (score <5) 22 (84.6) 50 (76.9) 0.563
Moderate (score 5–6) 4 (15.4) 13 (20.0)
Severe (Score 7–9) 0 (0.0) 2 (3.1)
Therapy of first AR
Methylprednisolone 16 (61.5) 39 (61.9) 0.397
Elevation of 
immunosuppression
7 (26.9) 10 (15.9)
Additional 
immunosuppression





0 (0.0) 4 (6.3)
Other medication 0 (0.0) 1 (1.6)
None 0 (0.0) 4 (6.3)
Abbreviations: AR, acute rejection; HCC, hepatocellular carcinoma.
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emphasize, as it excludes a bias of antiproliferative immu-
nosuppression on tumor recurrence.
Lai et al recently reported for the first time on the 
association between higher overall incidence of HCC 
recurrence and treatment of AR with steroid boluses.38 
They hypothesized that the usage of steroid boluses to 
manage AR and exposure to longstanding immunosup-
pression after AR treatment promotes HCC recurrence.38 
Based on our descriptive data, we cannot confirm or 
exclude causal links of steroid pulse therapy in episodes 
of AR and the risk of tumor recurrence. Interestingly, 65% 
of their matched control group consisted of patients with-
out occurrence of AR.38 Therefore, their hypothesis is not 
controversial to our assumption that AR itself as inflam-
matory immune response could be triggering oncogenesis. 
Nonetheless, our findings seem to elucidate possible links 
between modulating immune responses and HCC recur-
rence after LT. Furthermore, Decaens et al found histolo-
gically proven acute rejections to be associated with 
significantly worsened five-year HCC recurrence-free sur-
vival after LT.39
Second, AR might trigger the development of fibrosis 
in grafts through sustained sterile inflammation.40 In 
pediatric patients an association between antibody- 
mediated AR and progress of graft fibrosis leading to 
liver graft damage after LT was reported.41,42 
Furthermore, development and severity grade of liver 
fibrosis after LT is discussed as a potential predictor for 
death and graft loss in recipients.43 The chronically 
inflamed environment may promote carcinogenesis and 
may contribute to the increased frequency of tumor recur-
rence. This is supported by the papers suggesting 
Table 3 Patient Characteristics and Perioperative Outcomes Compared Between Patients with Early HCC Recurrence and Late HCC 
Recurrence
Early HCC Recurrence n=27n (%) Late HCC Recurrence n=20n (%) p-value
Gender (male:female) 25:2 17:3 0.404
Recipient age (in years) 60 (33–72) 59 (51–70) 0.575
Donor age (in years) 53 (12–84) 58 (24–78) 0.505
Alcohol 14 (51.9) 10 (50.0)
HCV 6 (22.2) 7 (35.0)
HBV 3 (11.1) 0 (0.0)
Other 4 (14.8) 3 (15.0)
AFP >200 µg/L 10 (37.0) 2 (11.8) 0.067
Time to transplant >120 days 11 (40.7) 8 (40.0) 0.959
Pretransplant MELD 10 (6–32) 12.5 (7–23) 0.358
Preoperative treatment 19 (70.4) 11 (55.0) 0.278
Mortality (%) 27 (100.0) 17 (85.0) 0.070
OS (months) 31 (20–82) 76 (28–165) <0.001a
NLR >4 9 (52.9) 7 (50.0) 0.870
CIT (min) 550 (18–1020) 712 (340–1119) 0.078
CIT >10 h 9 (33.3) 11 (55.0) 0.137
WIT (min) 45 (31–65) 47 (35–70) 0.191
WIT >50 min 4 (18.2) 5 (33.3) 0.292
T3/T4 stage 11 (40.7) 7 (35.0) 0.689
HCC bilobar 15 (55.6) 7 (35.0) 0.163
Poor differentiation (G >2) 9 (33.3) 8 (42.1) 0.544
Vascular invasion 12 (44.4) 7 (43.8) 0.965
Within MILAN 9 (33.3) 6 (30.0) 0.808
Acute rejection (Yes) 16 (59.3) 10 (50.0) 0.528
Extrahepatic recurrence 7 (25.9) 9 (45.0) 0.248
Intrahepatic recurrence 4 (14.8) 4 (20.0)
Both extra- and intrahepatic recurrence 16 (59.3) 7 (35.0)
Number of AR within 20 months 1 (0–3) 0.5 (0–3) 0.680
Note: aSignificant results. 
Abbreviations: HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; MELD, model for end-stage liver disease; OS, overall survival; NLR, neutrophil lymphocyte ratio; 
CIT, cold ischemia time; WIT, warm ischemia time.
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a subclass of HCC tumors is linked to markers of immune 
invasion.44 Furthermore, liver fibrosis might be a factor 
not only associated with late, but also early phase recur-
rence after curative liver treatment.10 Until today no 
reports on the correlation of AR related inflammation as 
potential stimulus for fibrosis and furthermore to HCC 
recurrence were found.
Third, our results suggest a potential immunological 
role of frequent AR on HCC recurrence. As Li et al 
already discussed, the inflammatory microenvironment 
may play critical roles on orchestrating cancer cells 
together with immune cells to facilitate tumor recurrence 
post-LT.23 Interestingly, Motomura et al reported preo-
perative higher IL17 levels to be significantly associated 
with higher NLR, leading to shorter recurrence free 
survival, whereas IL17 also seems to be associated 
with the prediction of AR after LT.23,45 Moreover, high 
expression of IL17 was identified to enhance the prolif-
eration in HBV-related HCC.46,47 In order to develop 
new markers for early phase liver graft injury leading 
to late phase tumor recurrence, we are in need of an 
improved understanding of the interplay between liver 
ischemia and inflammatory markers (eg IL17). In this 
regard, the role of immunoregulatory cells should be 
taken under focus.48 Of note, in patients with AR, hepa-
titis was found more frequently one year after LT, pos-
sibly contributing to development of fibrosis and 
recurrent disease.
As described widely in literature, patients with HCV 
need to be taken under special focus, since first IFN therapy 
can lead to more frequent episodes of AR and second, dis-
tinction between AR and HCV recurrence might be 
crucial.49 Therefore, we conducted a sub-analysis for this 
cohort, identifying no differences in regard to HCV viremia 
at the time of LT, HCV viremia duration post-LT, HCV 
recurrence and therapy of HCV (data not shown).
Our patient cohort was homogeneous, with a minimum 
length of follow-up of 20 months, with a sufficient observa-
tion time and regular post-LT check-ups. However, the 
results cannot be fully interpreted without considering spe-
cific limitations. The exclusion of patients who died before 
20 months may potentially create a selection bias. 
Table 4 Model 1 (AR as a Dichotomized Variable) and Model 2 (AR as a Continuous Variable): Analysis of Risk Factors for HCC 
Recurrence After OLT
Univariate Multivariable (Model 1) Multivariable (Model 2)
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
Recipient age 1.023 (0.982–1.066) 0.278
Donor age 0.998 (0.981–1.016) 0.833
Male recipient 0.447 (0.177–1.129) 0.088
Recipient BMI 0.997 (0.935–1.062) 0.915
Time to transplant >120 days 0.638 (0.356–1.144) 0.131
Previous hepatic resection 0.504 (0.212–1.200) 0.122
Previous RFA 0.706 (0.300–1.663) 0.426
Previous TACE 0.849 (0.476–1.515) 0.579
AFP >200 µg/L 3.007 (1.547–5.845) 0.001a 1.667 (0.587–4.737) 0.338 1.543 (0.520–4.579) 0.435
NLR >4 2.695 (1.331–5.454) 0.006a 3.735 (1.754–7.954) 0.001a 3.765 (1.757–8.069) 0.001a
CIT >10 h 1.349 (0.757–2.406) 0.310
WIT >50 min 0.708 (0.409–1.836) 0.708
Beyond MILAN 3.982 (2.155–7.357) <0.001a 1.357 (0.531–3.468) 0.523 1.178 (0.458–3.032) 0.734
Tumor size >5 cm 4.206 (2.322–7.619) <0.001a
>3 tumor nodules 2.153 (1.114–4.161) 0.022a
Bilobar 2.695 (1.519–4.782) 0.001a 2.527 (1.194–5.346) 0.015a 2.761 (1.305–5.840) 0.008a
T3/T4 4.690 (2.599–8.463) <0.001a 10.025 (4.121–24.388) <0.001a 9.181 (3.892–21.654) <0.001a
Vascular invasion 3.492 (1.911–6.381) <0.001a
Poor differentiation (G >2) 2.928 (1.607–5.335) <0.001a 1.750 (0.747–4.101) 0.197 1.897 (0.816–4.408) 0.137
AR (Yes) 2.389 (1.344–4.249) 0.003a 2.913 (1.299–6.532) 0.009a
Number of AR within 20 months 1.780 (1.348–2.350) <0.001a 1.805 (1.282–2.542) 0.001a
Note: aSignificant results. 
Abbreviations: BMI, body mass index; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; AFP, alpha-fetoprotein; NLR, neutrophil lymphocyte ratio; 
CIT, cold ischemia time; WIT, warm ischemia time; AR, acute rejection.
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Nevertheless, as shown in our supplemental analysis, no 
differences were noticed regarding the main hypothesis, 
that AR is associated with HCC recurrence. Of note, the 
study period of over 14 years at a single center must be 
reported as limitation. Therefore, in the long-term, results 
should be verified in a prospective study to mitigate the 
biases associated with a single center retrospective design. 
Nevertheless, serious consideration should be placed on the 
presence and frequency of AR within the first 20 months 
after LT as an early clinical marker for HCC recurrence. 
Therefore, those patients should be taken under special 
surveillance with the question of HCC recurrence.
Conclusion
The occurrence and frequency of episodes of AR within 
20 months after LT is associated with HCC recurrence. 
Our results have implications for monitoring and tumor 
surveillance after LT. Although we cannot prove causal 
links to graft fibrosis and immunological mechanisms, 
hypothesized interactions are worth further investigation.
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